Recombinant antibody fusion proteins for cancer immunotherapy.
Reisfeld
R A
RA
Scripps Research Institute, La Jolla, CA 92037, USA.
Gillies
S D
SD
D000818:Animals; D000912:Antibodies, Neoplasm / Q000235:genetics / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D016207:Cytokines / Q000235:genetics / Q000493:pharmacokinetics / Q000627:therapeutic use; D004815:Epidermal Growth Factor / Q000235:genetics / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000235:genetics / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology / Q000637:transplantation; D008233:Lymphotoxin-alpha / Q000235:genetics / Q000627:therapeutic use; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009447:Neuroblastoma / Q000556:secondary / Q000628:therapy; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018089:Superantigens / Q000235:genetics / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000912:Antibodies, Neoplasm; D016207:Cytokines; D018796:Immunoconjugates; D007376:Interleukin-2; D008233:Lymphotoxin-alpha; D011993:Recombinant Fusion Proteins; D018089:Superantigens; D004815:Epidermal Growth Factor